Adenoid cystic carcinoma

This early-stage trial is testing an experimental oral drug called RGT-61159 in about 105 people with two types of cancer that have come back or stopped responding to treatment: adenoid cystic carcinoma (a rare salivary gland cancer) and colorectal cancer. The main goals are to c…

Researchers are testing an experimental antibody called ONC-392 in people with advanced solid tumors, including non-small cell lung cancer and melanoma. The trial gives ONC-392 alone or with pembrolizumab, an approved immunotherapy, to see what doses are safe and how the body pro…

This early-stage study tests a new drug called E7389 liposomal formulation in people with advanced solid tumors that have not responded to standard treatments. The main goal is to find the safest dose and check for side effects. The study also looks at how the drug works in speci…

This phase 2 trial is testing whether an experimental drug called 9-ING-41, when combined with the chemotherapy drug carboplatin, can help people with advanced or metastatic salivary gland cancer. The study aims to see if the combination can shrink tumors or slow their growth. Pa…

This study tests a new drug called APG-115, alone or with chemotherapy, in people with a certain type of salivary gland cancer that has a normal p53 gene. The goal is to see if the drug can shrink tumors and to find the best dose with acceptable side effects. About 41 adults with…

This phase 2 trial is testing a combination of two immunotherapy drugs, nivolumab and ipilimumab, in 798 people with over 50 types of rare cancers. The goal is to see if these drugs can shrink tumors by helping the immune system attack cancer cells. Participants receive the drugs…

This study tests a combination of two drugs—pemetrexed (chemotherapy) and pembrolizumab (immunotherapy)—in people with salivary gland cancer that has returned or spread. The goal is to see if this combo can shrink tumors or slow the disease. About 45 adults with advanced salivary…

This study tests the drug lenvatinib in 33 people with advanced adenoid cystic carcinoma that has returned or spread. Lenvatinib is a daily pill that blocks cancer cell growth and cuts off blood supply to tumors. The main goal is to see if the drug can shrink tumors by at least 2…

This phase 2 trial tests whether amivantamab can shrink tumors or slow disease in 21 people with recurrent or metastatic adenoid cystic carcinoma, a rare salivary gland cancer. Participants receive weekly or biweekly infusions of the drug. The main goal is to see how many patient…

This study tests whether two drugs, lenvatinib and pembrolizumab, can shrink or slow the growth of advanced salivary gland cancers, including adenoid cystic carcinoma, that have come back or spread. About 64 participants will receive the combination therapy. The goal is to see ho…